48,439
edits
Difference between revisions of "Endometrial stromal sarcoma"
Jump to navigation
Jump to search
Endometrial stromal sarcoma (view source)
Revision as of 17:41, 20 March 2015
, 17:41, 20 March 2015no edit summary
(more) |
|||
| (9 intermediate revisions by the same user not shown) | |||
| Line 6: | Line 6: | ||
| Micro = highly cellular islands of (tumour) cells with a wavy irregular border -- benign uterine smooth muscle between; tumour cells: high [[NC ratio]] and epithelioid, pallisade around thin blood vessels within the tumour | | Micro = highly cellular islands of (tumour) cells with a wavy irregular border -- benign uterine smooth muscle between; tumour cells: high [[NC ratio]] and epithelioid, pallisade around thin blood vessels within the tumour | ||
| Subtypes = | | Subtypes = | ||
| LMDDx = [[leiomyoma]] (cellular), [[endometrial stromal nodule]], [[ | | LMDDx = [[leiomyoma]] (cellular), [[endometrial stromal nodule]], [[uterine leiomyosarcoma]], [[uterine tumour resembling an ovarian sex cord stromal tumour]] | ||
| Stains = | | Stains = | ||
| IHC = CD10 +ve, H-caldesmin -ve, PR +/-ve, ER +/-ve | | IHC = [[CD10]] +ve, H-caldesmin -ve, PR +/-ve, ER +/-ve | ||
| EM = | | EM = | ||
| Molecular = t(7;17) | | Molecular = t(7;17) | ||
| Line 24: | Line 24: | ||
| Rads = | | Rads = | ||
| Endoscopy = | | Endoscopy = | ||
| Prognosis = | | Prognosis = good | ||
| Other = | | Other = | ||
| ClinDDx = other [[uterine tumours]] | | ClinDDx = other [[uterine tumours]] | ||
| Line 30: | Line 30: | ||
'''Endometrial stromal sarcoma''', abbreviated '''ESS''', is a rare malignant mesenchymal [[uterine tumours|tumour of the uterus]]. | '''Endometrial stromal sarcoma''', abbreviated '''ESS''', is a rare malignant mesenchymal [[uterine tumours|tumour of the uterus]]. | ||
It is also known as '''low-grade endometrial stromal sarcoma''' | It is also known as '''low-grade endometrial stromal sarcoma''', abbreviated '''LGESS'''. | ||
==General== | ==General== | ||
*Uncommon.<ref name=pmid20179433> {{Cite journal | last1 = Chew | first1 = I. | last2 = Oliva | first2 = E. | title = Endometrial stromal sarcomas: a review of potential prognostic factors. | journal = Adv Anat Pathol | volume = 17 | issue = 2 | pages = 113-21 | month = Mar | year = 2010 | doi = 10.1097/PAP.0b013e3181cfb7c2 | PMID = 20179433 }}</ref> | *Uncommon.<ref name=pmid20179433> {{Cite journal | last1 = Chew | first1 = I. | last2 = Oliva | first2 = E. | title = Endometrial stromal sarcomas: a review of potential prognostic factors. | journal = Adv Anat Pathol | volume = 17 | issue = 2 | pages = 113-21 | month = Mar | year = 2010 | doi = 10.1097/PAP.0b013e3181cfb7c2 | PMID = 20179433 }}</ref> | ||
*Prognosis good.<ref name= | *Prognosis good<ref name=pmid24146786>{{Cite journal | last1 = Feng | first1 = W. | last2 = Malpica | first2 = A. | last3 = Skaland | first3 = I. | last4 = Gudlaugsson | first4 = E. | last5 = Robboy | first5 = SJ. | last6 = Dalen | first6 = I. | last7 = Hua | first7 = K. | last8 = Zhou | first8 = X. | last9 = Baak | first9 = JP. | title = Can proliferation biomarkers reliably predict recurrence in world health organization 2003 defined endometrial stromal sarcoma, low grade? | journal = PLoS One | volume = 8 | issue = 10 | pages = e75899 | month = | year = 2013 | doi = 10.1371/journal.pone.0075899 | PMID = 24146786 }}</ref> > 90% five year survival and > 85% ten year survival.<ref name=pmid24184602>{{Cite journal | last1 = Yoon | first1 = A. | last2 = Park | first2 = JY. | last3 = Park | first3 = JY. | last4 = Lee | first4 = YY. | last5 = Kim | first5 = TJ. | last6 = Choi | first6 = CH. | last7 = Bae | first7 = DS. | last8 = Kim | first8 = BG. | last9 = Lee | first9 = JW. | title = Prognostic factors and outcomes in endometrial stromal sarcoma with the 2009 FIGO staging system: A multicenter review of 114 cases. | journal = Gynecol Oncol | volume = | issue = | pages = | month = Oct | year = 2013 | doi = 10.1016/j.ygyno.2013.10.029 | PMID = 24184602 }}</ref> | ||
Note: | |||
*''Extrauterine endometrial stromal sarcoma'' is known as ''endometrioid stromal sarcoma''.<ref name=pmid24121169>{{Cite journal | last1 = Masand | first1 = RP. | last2 = Euscher | first2 = ED. | last3 = Deavers | first3 = MT. | last4 = Malpica | first4 = A. | title = Endometrioid stromal sarcoma: a clinicopathologic study of 63 cases. | journal = Am J Surg Pathol | volume = 37 | issue = 11 | pages = 1635-47 | month = Nov | year = 2013 | doi = 10.1097/PAS.0000000000000083 | PMID = 24121169 }}</ref> | |||
==Microscopic== | ==Microscopic== | ||
| Line 54: | Line 57: | ||
*[[Endometrial stromal nodule]]. | *[[Endometrial stromal nodule]]. | ||
*[[Uterine leiomyosarcoma]]. | *[[Uterine leiomyosarcoma]]. | ||
*[[Undifferentiated endometrial sarcoma]] (previously known as ''high-grade endometrial stromal sarcoma'') - necrosis and nuclear atypia.<ref name=pmid24146786/> | |||
*[[Uterine tumour resembling an ovarian sex cord stromal tumour]]. | |||
===Images=== | ===Images=== | ||
| Line 73: | Line 78: | ||
==IHC== | ==IHC== | ||
Features:<ref name=pmid14751141>{{Cite journal | last1 = Zhu | first1 = XQ. | last2 = Shi | first2 = YF. | last3 = Cheng | first3 = XD. | last4 = Zhao | first4 = CL. | last5 = Wu | first5 = YZ. | title = Immunohistochemical markers in differential diagnosis of endometrial stromal sarcoma and cellular leiomyoma. | journal = Gynecol Oncol | volume = 92 | issue = 1 | pages = 71-9 | month = Jan | year = 2004 | doi = | PMID = 14751141 }}</ref> | Features:<ref name=pmid14751141>{{Cite journal | last1 = Zhu | first1 = XQ. | last2 = Shi | first2 = YF. | last3 = Cheng | first3 = XD. | last4 = Zhao | first4 = CL. | last5 = Wu | first5 = YZ. | title = Immunohistochemical markers in differential diagnosis of endometrial stromal sarcoma and cellular leiomyoma. | journal = Gynecol Oncol | volume = 92 | issue = 1 | pages = 71-9 | month = Jan | year = 2004 | doi = | PMID = 14751141 }}</ref> | ||
*CD10 +ve. | *[[CD10]] +ve. | ||
*H-caldesmin -ve. | *H-caldesmin -ve. | ||
**[[Leiomyoma]]s +ve. | **[[Leiomyoma]]s +ve. | ||
*PR +/-ve. | *PR +/-ve. | ||
*ER +/-ve. | *ER +/-ve. | ||
*CD117 +ve (~80%).<ref>{{Cite journal | last1 = Park | first1 = JY. | last2 = Kim | first2 = KR. | last3 = Nam | first3 = JH. | title = Immunohistochemical analysis for therapeutic targets and prognostic markers in low-grade endometrial stromal sarcoma. | journal = Int J Gynecol Cancer | volume = 23 | issue = 1 | pages = 81-9 | month = Jan | year = 2013 | doi = 10.1097/IGC.0b013e3182738361 | PMID = 23221606 }}</ref> | |||
==Molecular== | ==Molecular== | ||